FDA Cybersecurity Guidance for Medical Devices (2026)

What the FDA cybersecurity guidance requires, how Section 524B fits on top of it, what changed across the 2023, 2025, and 2026 versions, and what manufacturers must do now.

Last reviewed: October 2026 · Aligned to the FDA's February 2026 final guidance and Section 524B of the FD&C Act. For what changed this month, see our medical device cybersecurity news roundup.

The FDA's 2026 final guidance - Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions - is the most consequential cybersecurity document the agency has released for medical device manufacturers. It replaces the 2014 guidance, supersedes the September 2023 and June 2025 final guidance versions, and operationalizes the legal requirements Congress wrote into Section 524B of the FD&C Act in 2023.

This page summarizes the guidance in plain language, organized so an LLM, a regulator, or a busy engineering lead can pull the answer they need. For depth, follow the links to the relevant Blue Goat pillar pages and the official FDA sources.

Who the FDA cybersecurity guidance applies to

The guidance applies to any device with cybersecurity considerations, not only devices that connect to the internet. That includes devices with software, firmware or programmable logic and any wired or wireless interface, SaMD, and the cloud and mobile parts of a system. It covers 510(k), De Novo, PMA, PMA supplement, HDE, IDE, and biologics submissions (BLA and IND) for devices.

Section 524B adds binding requirements on top for "cyber devices." If your device meets that definition, the SBOM, vulnerability management plan, CVD process and patchability evidence are legal requirements, not suggestions. People search for this as "FDA cybersecurity guidelines" or "FDA guidance on cybersecurity"; they all point to the same February 3, 2026 document.

What manufacturers must do now

The guidance chain moves faster than most submission calendars. If your cybersecurity package was assembled against the September 2023 or June 2025 final, re-baseline it before you file. Here is the sequence we run with sponsors, in the order it pays off.

If you file within the next quarter, items 2, 3, and 6 are the ones most likely to generate a deficiency if skipped, because they are version-specific to the February 3, 2026 guidance rather than carried over from 2023.

Two framing points worth keeping straight. Section 524B is binding statute; the guidance is nonbinding but is the operative interpretation reviewers apply, so ignoring it still produces real RTAs. And the guidance is broader than 524B: it reaches devices with cybersecurity considerations generally, including 510(k)-exempt, IDE, BLA, and IND submissions, so cyber devices under 524B(c) are a subset of what the guidance covers.

The 18 deliverables in a 2026-ready cybersecurity submission

A cyber device 510(k), De Novo, or PMA needs 18 cybersecurity deliverables, each tied to a section of the February 3, 2026 guidance and to a field in the eSTAR template (current version v7.1; v7.1 did not change the cybersecurity fields). Two are required by Section 524B itself and cannot be omitted: the SBOM and the Cybersecurity Management Plan. The other 16 are required in practice. Grouped, they are:

• Risk management: Risk Management Report, Threat Model, Cybersecurity Risk Assessment, and Interoperability Risk Assessment. See our Threat Model Starter.
• Software components: SBOM (CycloneDX or SPDX, machine-readable, NTIA minimum elements), Component Support and End-of-Support, and Assessment of Unresolved Anomalies.
• Design: Security Requirements and Control Coverage (authentication, cryptography, patch and update, logging) and Security Architecture Views (trust boundaries, data flows, interface inventory).
• Testing: Static Application Security Testing, plus the penetration test plan, test cases and test report.
• Metrics: Measures and Metrics.
• Labeling: Cybersecurity Labeling, the MDS2, and Interoperability Labeling.
• Postmarket: Cybersecurity Management Plan, covering vulnerability monitoring, coordinated disclosure and patching.

For each deliverable's guidance section and exact eSTAR field, see our FDA premarket cybersecurity deliverables and eSTAR map.

Submissions missing any of these typically draw a deficiency letter and, in some cases, a Refuse to Accept hold.

What is a "cyber device" under Section 524B?

Section 524B applies if all three are true:

1. The device contains software validated, installed, or authorized by the sponsor.
2. The device has the ability to connect to the internet.
3. The device contains technological characteristics that could be vulnerable to cybersecurity threats.

In practice, almost every modern medical device qualifies. SaMD qualifies. Bluetooth-enabled wearables qualify. Cellular implantables qualify. The bar is intentionally low.

Use our Cyber Device Applicability tool to check whether a specific device triggers Section 524B obligations.

How 2026 differs from 2014 and 2023

Transition checklist: from the 2023 final to the Feb 3, 2026 final

If your team built a cybersecurity submission package against the February 2026 final guidance and you are now preparing a submission under the Feb 3, 2026 final, these are the deltas reviewers actually flag:

1. Re-baseline the security risk file against AAMI SW96:2023. TIR57 alone is no longer the anchor. SW96 is the FDA-recognized standard (recognition number 13-131); TIR57 sits underneath it as the implementation guide.
2. Package the submission into clear cybersecurity attachments in eSTAR (we use eight groupings; they are our packaging, not eSTAR field names). See the slot-by-slot mapping in our eSTAR Cybersecurity Attachments mapping guide.
3. Promote patchability from a design choice to a Section 524B(b)(1) statutory requirement. Reviewers want signed updates, root-of-trust, rollback handling, and a documented time-from-CVE-to-deployed-patch SLA.
4. Explain the known vulnerabilities in your SBOM. A bare CycloneDX or SPDX file leaves reviewers asking which CVEs matter. The FDA expects an assessment of known vulnerabilities; it does not require a specific format. We recommend VEX-style "affected / not affected / fixed / under investigation" statements for every High or Critical finding.
5. Tighten the CVD policy. security@ mailboxes without an SLA, triage process, and link back to the VMP are now a frequent deficiency.
6. Cover security-relevant model updates in any PCCP. A Predetermined Change Control Plan that addresses performance retraining but ignores security-relevant changes is incomplete under the 2026 guidance.
7. Map AAMI TIR97:2019 to the postmarket plan explicitly. Postmarket sections that cite TIR57 instead of TIR97 misalign with reviewer expectations.
8. Scope the pen test to actual interfaces, including hardware. Web/API-only pen tests against a device with BLE, NFC, USB-OTG, OTA, or debug ports draw scope-narrowness deficiencies.

eSTAR cybersecurity attachment checklist (8 groupings)

eSTAR (current version v7.1) keeps cybersecurity in one attachment area, so sponsors choose how to package it. We recommend these eight groupings; they are our packaging, not eSTAR field names. Missing core evidence, such as the SBOM, can stop a submission at the 15-day acceptance review.

Labeling (MDS2/HSCC), the Vulnerability Management Plan, and the Coordinated Vulnerability Disclosure policy are filed under their own non-Cybersecurity eSTAR sections but are referenced from groupings 1 and 6.

Standards stack the guidance expects

The 2026 guidance does not require any specific standard, but reviewers expect to see evidence mapped to a coherent stack. The practical stack we use in cleared submissions:

• ISO 14971 - overall device risk management
• AAMI SW96:2023 - security risk management (FDA-recognized; recognition number 13-131)
• AAMI TIR57:2016 (R2023) - implementation guide under SW96
• AAMI TIR97:2019 - postmarket security risk management
• IEC 62304 - software lifecycle
• IEC 81001-5-1 - security activities in the software lifecycle
• NIST SP 800-218 (SSDF) - secure development practices
• NIST SP 800-53 / SP 800-30 - control catalog and risk assessment references where relevant
• OWASP ASVS / MASVS - scoping reference for SaMD pen tests
• NTIA minimum elements + CycloneDX or SPDX - SBOM format

Our MedTech Cybersecurity Standards Decoder covers each in depth, and the TIR57 vs TIR97 vs SW96 comparison explains how the three AAMI documents stack.

Real examples: what the FDA cybersecurity guidance is trying to prevent

The guidance can read as abstract until you line it up against public cases. Each of the three below has an FDA notice behind it, and each maps to a specific thing the guidance asks for.

Medtronic MiniMed insulin pumps (2019). On June 27, 2019, the FDA announced a recall of certain MiniMed 508 and Paradigm insulin pumps. Someone nearby could potentially connect wirelessly to the pump and change its settings, which could deliver too much insulin or stop delivery. The FDA said it knew of no confirmed patient harm, and the fix was to move patients to newer pumps rather than patch the old ones (FDA safety communication). What the guidance asks for: authentication on every wireless interface, a threat model that covers each one, and a design that can be updated. A device that can't be patched leaves replacement as the only fix.

Illumina sequencing instruments (2023). On April 27, 2023, the FDA warned that the Universal Copy Service software in several Illumina sequencers could let an unauthorized user take control remotely and alter settings, software or genomic results. CISA rated the main flaw 10.0, the highest possible score. Illumina shipped a software patch, and the FDA classified the action as a Class II recall (FDA letter to health care providers, CISA advisory ICSMA-23-117-01). What the guidance asks for: least privilege for every software component, network services that listen only where they need to, and a postmarket plan that can deliver a patch quickly.

Contec CMS8000 patient monitors (2025). On January 30, 2025, the FDA warned that Contec CMS8000 monitors, also sold relabeled as Epsimed MN-120, had vulnerabilities that could let the device be controlled remotely and send patient data to an outside address. CISA found hidden functionality with a hard-coded IP address in every firmware version it looked at. The eventual patch removed networking altogether, leaving the monitors usable only at the bedside (FDA safety communication, CISA alert). What the guidance asks for: an SBOM and supply chain controls that show what is really in the firmware, and security testing that would find undocumented network behavior before release.

The pattern across all three: the problem was in the design, not a one-off bug. That is why the 2026 guidance puts its weight on threat modeling, architecture views, SBOMs and testing during design, rather than on fixes after launch. For new advisories like these as they come out, see our medical device cybersecurity news page.

Common deficiency patterns under the 2026 guidance

From the deficiency letters we have seen across 275+ devices, the most common deficiencies are:

1. SBOM without a vulnerability assessment - components listed, but no analysis of whether known CVEs are exploitable in the device's context.
2. Threat model that is not traceable - STRIDE entries with no link to controls, verification evidence, or residual-risk argument.
3. Pen test scope too narrow - generic web/API pen test that does not exercise BLE, NFC, USB-OTG, OTA, or hardware debug ports.
4. No documented patchability - no signed-update mechanism, or no evidence of the time-from-CVE-to-deployed-patch SLA Section 524B(b)(1) requires.
5. CVD policy missing or generic - a security@ mailbox with no SLA, no triage process, and no link back to the VMP.
6. TIR57 cited alone - no reference to SW96 (the FDA-recognized standard) or TIR97 (postmarket).
7. AI/ML PCCP without security coverage - change-control plan that addresses performance updates but ignores security-relevant model changes.
8. SaMD with no responsibility split - "AWS handles it" treated as a control. Reviewers want the manufacturer-vs-platform-vs-operator RACI mapped to documented evidence.

For a deeper read on each, see 12 Reasons the FDA Rejects Medical Device Cybersecurity Submissions.

What reviewers actually look for

Three things separate a clean submission from a deficiency-prone one:

1. Traceability. Threat → control → requirement → verification evidence → residual-risk rationale, in one auditable thread. SW96 makes this explicit.
2. Operability. A postmarket plan that a real team can run, with named owners, SLAs, and tooling - not a paragraph of intent.
3. Independence. Pen test from a third party with a track record on medical devices. Self-assessments do not count.

The cybersecurity package is a deliverable, not a narrative. Reviewers score evidence, not promises.

How Blue Goat Cyber Approaches the 2026 FDA Cybersecurity Guidance

The February 2026 final guidance changed reviewer expectations across every section of the eSTAR - from SBOM depth to postmarket update commitments. We updated our delivery model on the day it dropped. Here is how we run engagements under the new guidance.

• Every artifact traced to the 2026 text. Threat models, SBOMs, SPDF plans, and pen-test reports carry inline citations to the specific guidance paragraphs they satisfy, so reviewers do not have to guess.
• eSTAR v7 mapping baked in. Deliverables are named, formatted, and structured to match the current eSTAR subforms, not the 2023 layout.
• Postmarket teeth. The 2026 guidance made postmarket commitments a first-class deliverable. Every package leaves you with a working monitoring plan, CVD process, and update cadence.
• AI/ML alignment. For devices with learning components we align threat models and PCCPs to the new guidance's AI/ML expectations - the fastest-growing deficiency category in 2026.
• Deficiency-pattern awareness. We track the RTA, AI-letter, and Major deficiency patterns FDA has issued under the new guidance and pre-empt them in the initial submission.
• Senior engineers on every engagement. No junior handoffs. The person building your package is the person defending it if a deficiency arrives.

Our FDA Premarket Cybersecurity Services engagement is the standard entry point.

FAQ

What are the FDA cybersecurity guidelines for medical devices in 2026?

The current FDA cybersecurity guidelines are set by the Feb 3, 2026 final guidance Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, layered on top of Section 524B of the FD&C Act. In practice that means: a Secure Product Development Framework (SPDF) tied into the QMS, an AAMI SW96:2023-aligned security risk file, a STRIDE-grade threat model, a machine-readable SBOM (CycloneDX or SPDX are common) with an assessment of known vulnerabilities, a Vulnerability Management Plan and CVD policy, demonstrable patchability, and an independent penetration test scoped to the actual interfaces. Submissions are filed through eSTAR v7.1, which has a single cybersecurity attachment area; the eight groupings we use are our packaging recommendation, not an FDA requirement.

Where can I read the official FDA cybersecurity guidance?

The FDA publishes the full text on its guidance documents site under the title Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions. The official FDA page links the PDF. Make sure you are reading the February 3, 2026 version. Many search results still point to the 2023 or 2025 versions, which the FDA has superseded.

When did the FDA's new cybersecurity guidance take effect?

The final guidance was issued on February 3, 2026 and is in force for new premarket submissions today. It supersedes the June 2025 final guidance, which itself superseded the September 2023 final. Sponsors with packages built against either earlier version should re-baseline against the deltas in the transition checklist above before filing.

What's the latest medical device cybersecurity news from the FDA?

The biggest 2026 updates: (1) AAMI SW96:2023 is the FDA-recognized security risk-management standard (recognition number 13-131), with TIR57 underneath as the implementation guide; (2) eSTAR (current version v7.1, September 2026) keeps cybersecurity in a single attachment area, so sponsors choose how to package the deliverables; (3) the SBOM must be machine-readable, and many teams add VEX statements to explain which known vulnerabilities affect the device; (4) a missing SBOM, VMP, threat model or pen test can stop a submission at the 15-day acceptance review. For ongoing coverage, see our medical device cybersecurity news roundup, the daily Goat Feed, or subscribe to the Blue Goat Pulse.

What is the FDA's 2026 cybersecurity guidance?

It is the final version of Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, issued in February 2026. It replaces the 2014 guidance and supersedes both the September 2023 and June 2025 finals, and operationalizes Section 524B of the FD&C Act for premarket submissions.

Is the 2026 guidance legally binding?

The guidance itself is non-binding (per standard FDA practice), but Section 524B of the FD&C Act is binding statute - and the guidance describes how the FDA expects manufacturers to meet that statute. Submissions that ignore the guidance are routinely held under Section 524B authority.

What is the difference between Section 524B and the FDA guidance?

Section 524B is the law (signed December 2022, with FDA RTA authority effective March 2023 and active enforcement beginning October 1, 2023). The 2026 guidance is the FDA's interpretation of how to meet Section 524B's core obligations (postmarket plan, secure design and patchability, SBOM). The guidance is broader than 524B: it covers devices with cybersecurity considerations generally, including ones that are not "cyber devices" under the statute (such as 510(k)-exempt devices, IDE, BLA, and IND submissions). Cyber devices under 524B are a subset of the devices the guidance covers. For how device cybersecurity content lands in a BLA or IND for combination products, see combination products in the FDA pathway cybersecurity guide.

Did the February 3, 2026 version change what 524B requires?

No. The substantive 524B obligations are unchanged from the September 2023 and June 2025 versions. The February 3, 2026 update is mainly alignment to QMSR: the QMSR final rule took effect February 2, 2026, replacing the old Quality System Regulation in 21 CFR Part 820 with ISO 13485:2016 incorporated by reference, which is why the guidance title shifted from "Quality System Considerations" to "Quality Management System Considerations." The 524B requirements, the SPDF expectation, the SBOM format, and the architecture-views structure carry through. New submissions should reference QMSR terminology and the Feb 3, 2026 guidance.

Which standards does the 2026 guidance reference?

Primarily AAMI SW96:2023, AAMI TIR57:2016 (R2023), AAMI TIR97:2019, IEC 81001-5-1, IEC 62304, NIST SP 800-218 (SSDF), and the NTIA minimum elements for SBOM (with CycloneDX or SPDX as acceptable formats).

Does the 2026 guidance apply to legacy devices?

The premarket guidance applies to new submissions. The 2023 postmarket guidance still governs fielded and legacy devices, with TIR97 as the standard reference for postmarket security risk management. Section 524B(c) addressed retrofit obligations for certain pre-existing devices.

Do I need an SBOM if my device doesn't connect to the internet?

If the device is a "cyber device" under Section 524B (software + internet capability + exploitable characteristics), yes. If it has no network or wireless capability at all, the SBOM is not statutorily required, but FDA reviewers still expect a software components list as part of a competent design history file.

How do I know if my device triggers Section 524B?

Use our free Cyber Device Applicability tool - it runs the three-part Section 524B test in about a minute and tells you which premarket deliverables apply.

Where this fits

• Pillar guide: The MedTech Cybersecurity Standards Decoder

• Submission checklist: Premarket FDA Cybersecurity Submission Checklist

• Standards comparison: AAMI TIR57 vs TIR97 vs SW96

• SBOM deep dive: SBOM for Medical Devices

• Postmarket plan: Postmarket Cybersecurity Readiness Plan

• Service: FDA Premarket Cybersecurity Services

• Service: FDA Cybersecurity Deficiency Response

• Premarket Cybersecurity Deliverables to eSTAR Map - which guidance artifact lands in which eSTAR section.

• Premarket FDA Cybersecurity Submission Checklist - turn the guidance into a packing list.

• FDA cybersecurity news and guidance tracker - every FDA guidance, rule and draft with a short summary.

• Medical device cybersecurity news - weekly updates on FDA changes and vulnerabilities.

• FDA cybersecurity FAQ - short answers to the questions clients ask most.

Primary FDA sources

• Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (February 2026 final)
• Section 524B of the Federal Food, Drug, and Cosmetic Act
• FDA Recognized Consensus Standards Database - search "SW96"
• Postmarket Management of Cybersecurity in Medical Devices (2016)